Uwe S. Schlegel

Measuring affective, cognitive and behavioral responses to fatigue: validation of the Avoidance-Endurance Questionnaire adaptation to fatigue (AEQ-F) in patients with brain cancer

Monika Ilona Hasenbring, Christina Titze, Uwe S. Schlegel, Thomas E. Kowalski

Objective: A number of studies supported the role of fear-avoidance (FAR) and endurance-related responses (ER) to fatigue in the maintenance of symptoms associated with chronic diseases. However, reliable and valid measures of fatigue-related FAR and ER are lacking. This study aimed to …

de, ch (code pays fourni par la source)

„Revolution im biologischen Verständnis und neue Strategien in der Therapie“

Ghazaleh Tabatabai, Uwe S. Schlegel

Neuroonkologie: Herausforderungen und Perspektiven

Ghazaleh Tabatabai, Uwe S. Schlegel

de, ch (code pays fourni par la source)

Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Thomas Zeyen, Daniel Paech, Johannes M Weller, Niklas Schäfer et autres

de, ch (code pays fourni par la source)

BIOM-13. ASSOCIATION OF HAND-FOOT SKIN REACTIONS WITH SURVIVAL IN RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH REGORAFENIB

Jan‐Michael Werner, Peter Hau, Thomas E. Kowalski, Hannes Treiber et autres

Abstract INTRODUCTION The phase 2 REGOMA trial suggested a survival benefit of the multikinase inhibitor regorafenib for treating patients with glioblastoma at first recurrence. Hand-foot skin reactions (HFSR) following multikinase inhibitor therapy have been reported to predict prolonged overall survival (OS) in …

de, ch (code pays fourni par la source)

BIOM-64. A PROGNOSTIC SCORING SYSTEM FOR IMMUNODEFICIENCY-ASSOCIATED PRIMARY CNS LYMPHOMAS: AN INTERNATIONAL MULTI-CENTER STUDY

Philipp Karschnia, Benjamin-Leon Traub, Sofia Doubrovinskaia, Benjamin I. Richter et autres

Abstract BACKGROUND Immunodeficiency-associated (ID-) primary CNS lymphomas (PCNSL) were introduced as a distinct entity in the 2021 World Health Organization classification of brain tumors. Given their rarity, larger clinical studies and prognostic models to guide management are lacking. METHODS PCNSL, newly diagnosed …

de, us (code pays fourni par la source)

Therapie und Verlauf neurologischer Erkrankungen

Benedikt G. H. Schoser, Jörg Bernhard Schulz, Volker H. Dietz, Voica Ghilescu et autres

Das große Standardwerk zur klinischen Neurologie liegt jetzt unter der Federführung des international renommierten Herausgeberteams und der Mitarbeit von über 150 FachexpertInnen als erweiterte und komplett überarbeitete Neuauflage vor. Die aktuellen Erkenntnisse zum Stand von Klinik, Verlauf und Therapie neurologischer Erkrankungen werden …

P11.20.B ASSOCIATION OF HAND-FOOT SKIN REACTIONS WITH SURVIVAL IN RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH REGORAFENIB

Jan‐Michael Werner, Peter Hau, ThomasE Kowalski, Hannes Treiber et autres

Abstract BACKGROUND The phase 2 REGOMA trial suggested a survival benefit of the multikinase inhibitor regorafenib for the treatment of patients with glioblastoma at first recurrence. Hand-foot skin reactions (HFSR) following multikinase inhibitor therapy have been reported as a predictor for prolonged …

de, ch (code pays fourni par la source)

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Thomas Zeyen, Daniel Paech, Johannes M Weller, Niklas Schäfer et autres

Abstract Purpose In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and pseudoprogression rates (about 10%) were similar in both arms. Further evaluating this discrepancy, we analyzed patterns …

de, ch (code pays fourni par la source)

Hirnmetastasen und Meningeosis carcinomatosa solider Tumoren

Sabine Seidel, Uwe S. Schlegel

All articles of this category (opens in new window) Zerebrale Metastasen oder eine Meningeosis neoplastica treten im Verlauf einer Tumorerkrankung relativ häufig auf und gehen auch heute noch mit einer relevanten Morbidität und Mortalität einher. Insbesondere die Therapierbarkeit zerebraler Metastasen hat sich …

Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up

Milena Pertz, Sabine Schlömer, Clemens Seidel, Bettina Hentschel et autres

PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients' neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal treatment with neurocognition with a particular focus …

de, ch (code pays fourni par la source)

Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients

Milena Pertz, Sabine Schlömer, Clemens Seidel, Bettina Hentschel et autres

\(\bf Purpose\) Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal treatment with neurocognition with a particular …